Crystal structures of VIM-1 complexes explain active site heterogeneity in VIM-class metallo-β-lactamases by Salimraj, Ramya et al.
                          Salimraj, R., Hinchliffe, P., Kosmopoulou, M., Tyrrell, J. M., Brem, J., van
Berkel, S. S., ... Spencer, J. (2019). Crystal structures of VIM-1 complexes
explain active site heterogeneity in VIM-class metallo--lactamases. FEBS
Journal, 286(1), 169-183. https://doi.org/10.1111/febs.14695
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1111/febs.14695
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Wiley at
https://febs.onlinelibrary.wiley.com/doi/full/10.1111/febs.14695 . Please refer to any applicable terms of use of
the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Crystal structures of VIM-1 complexes explain active site
heterogeneity in VIM-class metallo-b-lactamases
Ramya Salimraj1, Philip Hinchliffe1, Magda Kosmopoulou1, Jonathan M. Tyrrell2, J€urgen Brem3,
Sander S. van Berkel3, Anil Verma4, Raymond J. Owens4, Michael A. McDonough3,
Timothy R. Walsh2, Christopher J. Schofield3 and James Spencer1
1 School of Cellular and Molecular Medicine, University of Bristol, UK
2 Institute of Infection and Immunity, Cardiff University, UK
3 Department of Chemistry, University of Oxford, UK
4 Oxford Protein Production Facility UK, Rutherford Appleton Laboratory, Oxfordshire, UK
Keywords
antibiotic resistance; carbapenem; metallo-b-
lactamase; VIM; X-ray crystallography
Correspondence
J. Spencer, School of Cellular and Molecular
Medicine, University of Bristol School of
Medical Sciences, University Walk, Bristol
BS8 1TD, UK
Fax: +44 0 117 331 2091
Tel: +44 0 117 331 2084
E-mail: jim.spencer@bristol.ac.uk
(Received 18 June 2018, revised 6 October
2018, accepted 2 November 2018)
doi:10.1111/febs.14695
Metallo-b-Lactamases (MBLs) protect bacteria from almost all b-lactam
antibiotics. Verona integron-encoded MBL (VIM) enzymes are among the
most clinically important MBLs, with VIM-1 increasing in carbapenem-
resistant Enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae) that
are among the hardest bacterial pathogens to treat. VIM enzymes display
sequence variation at residues (224 and 228) that in related MBLs are con-
served and participate in substrate binding. How they accommodate this
variability, while retaining catalytic efficiency against a broad substrate
range, has remained unclear. Here, we present crystal structures of VIM-1
and its complexes with a substrate-mimicking thioenolate inhibitor,
ML302F, that restores meropenem activity against a range of VIM-1 produc-
ing clinical strains, and the hydrolysed product of the carbapenem merope-
nem. Comparison of these two structures identifies a water-mediated
hydrogen bond, between the carboxylate group of substrate/inhibitor and
the backbone carbonyl of the active site zinc ligand Cys221, that is common
to both complexes. Structural comparisons show that the responsible
Cys221-bound water is observed in all known VIM structures, participates in
carboxylate binding with other inhibitor classes, and thus effectively repli-
cates the role of the conserved Lys224 in analogous complexes with other
MBLs. These results provide a mechanism for substrate binding that permits
the variation at positions 224 and 228 that is a hallmark of VIMMBLs.
Enzymes
EC 3.5.2.6
Databases
Co-ordinates and structure factors for protein structures described in this manuscript have been
deposited in the Protein Data Bank (www.rcsb.org/pdb) with accession codes 5N5G (VIM-1),
5N5H (VIM-1:ML302F complex) and 5N5I (VIM-1-hydrolysed meropenem complex).
Abbreviations
MBL, metallo-b-lactamase; VIM, Verona Integron-encoded MBL.
169The FEBS Journal 286 (2019) 169–184 ª 2018 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
Introduction
Antibiotic resistance is of immediate and growing con-
cern to global public health [1]. Resistance in oppor-
tunistic Gram-negative bacterial pathogens is of
pressing importance as these organisms cause an
increasing frequency of healthcare-associated infections
in immunocompromised individuals and treatment
options are limited by both intrinsic and acquired
resistance mechanisms [2]. b-Lactams, which continue
to form over half of the global antibacterial market
[3], remain key agents for treatment of such infections,
with the carbapenems in particular rapidly supplanting
third-generation cephalosporins as first-choice drugs.
In pathogens such as the Enterobacteriaceae (e.g.
Escherichia coli; Klebsiella pneumoniae) or nonferment-
ing organisms (e.g. Pseudomonas aeruginosa; Acineto-
bacter baumannii) production of b-lactamases that
inactivate b-lactams via hydrolysis of the b-lactam ring
[4], is the major form of b-lactam resistance [5]. Over
1300 such enzymes have now been identified in isolates
of diverse clinical origin [6]. While the spectrum of
activity against different b-lactam classes varies
between enzymes, carbapenem-hydrolysing b-lacta-
mases are attracting increasing attention due to the
efficiency with which they hydrolyse most b-lactam
classes and the growing frequency with which they are
isolated from patients [7].
b-Lactamases comprise two distinct groups – serine
(SBL) and metallo- (MBL) b-lactamases – which differ
in their structure and catalytic mechanisms [8]. Clini-
cally available inhibitors (e.g. clavulanic acid, avibac-
tam) are active against many, though not all, SBLs
but all are ineffective against the MBLs [9]. In addi-
tion, while carbapenems effectively inhibit most SBLs
[10], all known MBLs effectively hydrolyse these
antibiotics [11]. In consequence, MBL dissemination
poses a particular challenge to the continued effective-
ness of b-lactams, especially carbapenems, against
Gram-negative bacteria.
Metallo-b-lactamases possess a conserved protein
fold that forms an abba sandwich with the active site
zinc centre found in a central groove on one edge of
the two b-sheets [12]. Based upon differences in
sequence and active site structures, the MBLs are
divided into three subgroups (B1, B2 and B3 [13]) with
the most clinically relevant IMP, VIM and NDM
enzymes [14] contained within the subclass B1. The B1
active site binds two zinc ions, located respectively in
the (usually tetrahedral) Zn1 site formed by the con-
served histidines 116, 118 and 196; and the Zn2 site
comprising Asp120, Cys221 and His263 [15]. (The
standard MBL numbering scheme [16] is used
throughout.) It is generally accepted that B1 enzymes
require both zinc sites for maximal catalytic efficiency
[17,18].
The VIM (Verona Integron-encoded MBL) enzymes
are one of the most widely distributed MBL families
and are a leading cause of carbapenem failure, particu-
larly in P. aeruginosa [19]. blaVIM-1 was identified in
1999 as a chromosomally encoded gene on a cassette
within a class I integron in a P. aeuruginosa clinical
isolate from Italy [20]. Subsequently, VIM enzymes
have been identified on ‘multiresistance’ plasmids from
multiple Gram-negative species; over 50 different VIM
variants have now been identified [21]. Of these, VIM-
1 is noteworthy as it is most frequently encountered in
the Enterobacteriaceae (K. pneumoniae and E. coli
[22]); most other VIM types are primarily associated
with the less common nonfermenting pathogens, in
particular P. aeruginosa. VIM (and other B1) MBLs
have a broad spectrum of activity encompassing peni-
cillins, cephalosporins and carbapenems ([23] and ref-
erences therein).
Sequence identity between VIM variants ranges
from ~ 75% to > 99%, with VIM-1 and VIM-2 pro-
genitors of two dominant phylogenetic clusters and
VIM-7 as a uniquely divergent variant [23]. Sequence
substitutions at residues 224 and 228 are a hallmark of
VIM variants and of particular interest as these posi-
tions interact with b-lactam substrates in other MBLs
[24,25]. Although several crystal structures of VIM
enzymes are now available [24,26–28], including of the
VIM-1 point variants VIM-4 [29], and VIM-26 [25],
structures of the progenitor enzyme VIM-1 have not
previously been reported. Notably, from both inhibitor
design and mechanistic perspectives, there is as yet no
structural information describing how any VIM
enzyme binds b-lactams. Here, we focus on structural
investigations of VIM-1 and its interactions with a
non-b-lactam inhibitor that mimics b-lactam binding,
ML302F [30], as well as a clinically relevant car-
bapenem substrate, meropenem. Our results reveal
how substrate/inhibitor binding by VIM enzymes is
tolerant of substitutions at sequence positions that in
other MBLs make interactions, notably those involv-
ing the b-lactam carboxylate, that are crucial for
activity.
Results
Crystal structure of VIM-1
Crystals of VIM-1 formed after several days’ incuba-
tion at 20 °C and diffracted to near atomic resolution
(1.29 A; Table 1). Initial analysis showed these to be
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of space group P 21 with a solvent content of 41.4%,
indicating one molecule in the asymmetric unit. Struc-
ture solution by molecular replacement, and subse-
quent model building, were straightforward, with the
complete chain traced without interruption between
residues Gly25 and His293 giving a final model con-
taining 233 residues. The structure displays the overall
ab/ba fold of the MBL superfamily, with the binuclear
zinc centre that forms the active site situated in a shal-
low groove formed by the interface of the two ab
domains (Fig. 1A). Two extended loops, termed L3
(residues 60–66) and L10 (residues 221–241) border the
active site. Superposition of the VIM-1 structure with
those of other VIM family members using PDBEFOLD
[31] yields RMSD values for Ca-atoms of between
0.28 A (VIM-26, pdb 4UWP [25]) and 0.83 A (VIM-
31 (oxidized) pdb 4FSB [28]) A, demonstrating that
only small differences are evident between the overall
fold of VIM-1 and other structurally characterized
VIM variants (Fig. 1B). These differences are largely
localized to the L3, and to a lesser extent the L10,
loops.
Metal ions observed in both metal sites were refined
as zinc ions, with occupancies of 0.94 (Zn1) and 0.73
(Zn2), respectively. Although reduced occupancy was
observed for the Zn2 site, the Cys221 ligand was
refined as the fully reduced form. An additional zinc
ion was present (occupancy 0.54) bound to a bicine
buffer molecule at the protein surface. The two active
site zinc ions are separated by a distance of 3.62 A
with Zn1 in a tetrahedral geometry and Zn2 showing
octahedral coordination with one vacant position [32]
(Fig. 1C). Two well-defined water molecules are pre-
sent in the active site: a bridging water/hydroxide
Table 1. Data collection and refinement statistics.
Native VIM-1 VIM-1:ML302F VIM-1:Meropenem
Data collection
X-ray source DLS (I04) DLS (I02) DLS (I24)
Wavelength (A) 0.9795 0.9795 0.9686
Space group P21 P21 P21
Cell dimensions
a, b, c (A) 39.76, 67.94, 40.36 39.68, 67.65, 40.22 38.94, 68.08, 39.82
a, b, c 90, 94.01, 90 90, 91.36, 90 90, 90, 90
Molecules/asymmetric unit 1 1 1
Resolution (A) 40.26–1.29 (1.31–1.29) 28.58–1.30 (1.32–1.30) 27.84–2.20 (2.28–2.20)
No. of unique reflections 61 346 52 058 10 547
Redundancy 3.6 (3.4) 6.4 (6.1) 5.8 (5.7)
Rpim 0.039 (0.326) 0.033 (0.201) 0.081 (0.240)
CC1/2 0.997 (0.763) 0.997 (0.881) 0.988 (0.870)
I/r(I) 12.5 (2.9) 21.5 (7.9) 8.5 (4.2)
Completeness (%) 99.3 (98.7) 99.8 (99.4) 99.2 (98.6)
Refinement
Resolution (A) 34.25–1.29 28.58–1.30 27.84–2.20
No. of reflections 53 159 52 032 10 543
Rwork/Rfree 0.1445/0.1563 0.1545/0.1678 0.1526/0.2250
Atoms
Protein 3432 3496 1755
Ligand N/A 19 27
Zinc 3 2 3
Solvent 328 237 85
B-factor (A2)
Protein 15.19 15.32 16.99
Ligand N/A 15.96 39.13
Zinc 16.15 8.34 25.96
Solvent 29.62 28.42 22.35
RMSD
Bonds (A) 0.008 0.020 0.006
Angles (°) 1.262 1.672 1.076
PDB accession 5N5G 5N5H 5N5I
5% of reflections were set aside for Rfree calculation. IMOSFLM, XDS, AIMLESS and PHASER MR were used for structure solution and PHENIX for
refinement.
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(Wat1, B-factor 14.65 A2) positioned asymmetrically
between the two zinc ions, lying closer (1.89 A) to Zn1
than to Zn2 (2.18 A); and a second water molecule
(Wat2, B-factor 21.67 A2) apparently tightly (2.06 A)
bound to Zn2.
Functionally significant differences between VIM
variants have been associated primarily with substitu-
tions at positions 224 and 228 on loop L10 [23,26]
where VIM-1 possesses His and Ser residues, respec-
tively (Fig. 2A). Notably, in our VIM-1 structure
His224 is oriented by a strong hydrogen bond (2.92 A)
between Oc of Ser228 and Nd1 of His224, such that
the side chain imidazole ring forms one wall of the
active site cleft (Fig. 2A). In contrast, in structures of
enzymes such as VIM-4, VIM-7 and VIM-31, His224
Nd1 instead is H bonded to Nx1 of Arg228, appar-
ently causing rotation of the His224 side chain to lie
perpendicular to its position in VIM-1 [27–29]. In
VIM-1, the orientation of the His224 side chain more
closely resembles that of the phenolic ring of Tyr224
Fig. 1. Crystal structure of VIM-1. (A) View of the crystal structure of di-zinc VIM-1 showing the overall fold and location of active site.
Protein main chain is colour-ramped from blue (N terminus) to red (C terminus). Active site residues are rendered as sticks; zinc ions as
grey spheres. Secondary structure elements are labelled. (B) Superposition of di-zinc VIM-1 with structures of other VIM enzymes (VIM-2,
pdb 4BZ3; VIM-4, pdb 2WHG; VIM-5, pdb 5A87; VIM-7, pdb 4D1T; VIM-26, pdb 4UWO; VIM-31, pdb 4FR7; coloured as shown). (C)
Stereoview of di-zinc VIM-1 active site. Electron density shown is 2|Fo|  |Fc| Φcalc contoured at 1.5 r. This Figure was created using PYMOL
(www.pymol.org).
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in VIM-2 (Fig. 2B). Moreover, in the VIM-2, -4, -7
and -31 structures, the side chain of Arg228 protrudes
into the active site groove towards the side chain of
Tyr67, which is located at the base of the L3 loop on
the opposite side of the cleft. Thus, substitution of
Arg228 for Ser in VIM-1 (and in VIM-26 [25] where
His224 is substituted by Leu) expands the active site
cleft compared to other VIM enzymes of known struc-
ture.
Inhibition of VIM-1 by the thioenolate ML302F
Despite their sequence differences, and the growing
clinical importance of VIM-1, many studies of MBL
inhibitors have used VIM-2 as a representative VIM
enzyme. Recently, we reported that the thioenolate
hydrolysis product, ML302F, of the rhodanine
ML302, is a potent (submicromolar) inhibitor of both
VIM-1 and VIM-2 in vitro [30], and proposed that
ML302F binding to MBLs mimics that of b-lactam
substrates/intermediates. Accordingly, we sought to
extend these findings by studying the interactions of
ML302F with VIM-1 in producer bacteria and by
X-ray crystallography.
To investigate interactions of ML302F with VIM-1
in bacteria, we determined minimal inhibitory concen-
trations (MICs) for the clinically important car-
bapenem antibiotic meropenem by broth microdilution
for 27 VIM-1 expressing K. pneumoniae and E. coli
clinical strains in the presence and absence of
10 lgmL1 ML302F (Table 2). All 20 K. pneumoniae
strains could be considered as resistant to meropenem
according to either CLSI or EUCAST clinical break-
points; however, only two of seven E. coli could be
classed as resistant, with the rest showing meropenem
susceptibility that, while substantially reduced com-
pared to control, was still within the susceptible range.
For 8 of 20 K. pneumoniae strains, the meropenem
MIC in the presence of ML302F changes from resis-
tant to susceptible according to EUCAST breakpoints,
with a further six strains changing from resistant to
intermediate susceptibility. Of the remaining six strains
tested, five showed MIC reductions in one (twofold) to
two (fourfold) dilutions, with one being unaffected.
ML302F reduced the meropenem MICs of the two
resistant E. coli strains to susceptible in one case and
to intermediate in the other. In the five susceptible
strains, reductions in at least two dilutions (fourfold or
Fig. 2. Comparison of VIM active sites. (A) Active site of VIM-1, showing positions of His224 and Ser228 and location of Cys221-bound
water Wat3. Hydrogen bonding interactions are shown as dashed lines. (B) Active site superpositions of VIM-2 (pdb 4BZ3, blue) and VIM-4
(pdb 2WHG, red) showing variations at positions 224 and 228.
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more) were observed in four cases, with one
strain apparently unaffected. These results show that
ML302F can potentiate the activity of meropenem
against clinical isolates of VIM-1 expressing Enter-
obacteriaceae, and thus that this compound can pene-
trate clinically relevant bacteria to act as an effective
inhibitor of VIM-1 in the bacterial host.
Crystal structure of VIM-1:ML302F complex
We next sought to obtain structural information on
the binding of ML302F to VIM-1. An ML302F:VIM-
1 complex was obtained from a cocrystal, of the same
symmetry as native VIM-1, that yielded a diffraction
dataset complete to 1.30 A resolution. Two hundred
and thirty-four amino acids were built into this
structure with four amino acids missing from the N
terminus, and two from the C terminus. Five residues
were built with alternative conformations. The Zn1 site
was modelled with occupancy of 1.0, and the Zn2 site
with occupancy 0.94. Initial electron density maps fea-
tured positive difference peaks in the active site that
indicated the likely presence of bound ligand and into
which ML302F could be readily fitted (Fig. 3A).
ML302F was refined with occupancy 0.91 with a B-
factor (15.96 A2) comparable to that of the protein
(15.32 A2).
Binding of ML302F (Fig. 3) manifests displacement
of the di-zinc ion bridging water molecule Wat1 by the
inhibitor thiol, which intercalates between the two zinc
ions (distances 2.32 and 2.38 A from Zn1 and Zn2
respectively). The inhibitor carboxylate displaces Wat2
Table 2. Effect of ML302F on meropenem MICs for VIM-1-expressing enterobacteriaceae.
Strain
Meropenem
MIC (lgmL1)
Meropenem
resistant/intermediate/
susceptible (clinical
strains; EUCASTa)
Meropenem MIC (lgmL1)
+ 10 lgmL1 ML302F
Meropenem
resistant/intermediate/
susceptible
(clinical strains; EUCASTa)
Fold difference
in MIC
Escherichia coli
TOP1O (control)
≤ 0.25 ≤ 0.25 0
Klebsiella pneumoniae
NCTC 5055 (control)
≤ 0.25 ≤ 0.25 0
K. pneumoniae Kpn20 32 R 8 R 4
K. pneumoniae 08Y70 32 R 2 S 16
K. pneumoniae 08Z37 16 R 4 I 4
K. pneumoniae 09A69 32 R 4 I 8
K. pneumoniae 09B51 8 R 1 S 8
K. pneumoniae 09B53 8 R 1 S 8
K. pneumoniae 09B61 32 R 4 I 8
K. pneumoniae 09B76 64 R 32 R 2
K. pneumoniae 09C12 64 R 16 R 4
K. pneumoniae 09C74 256 R 128 R 2
K. pneumoniae 09C77 32 R 4 I 8
K. pneumoniae 09D21 16 R 1 S 16
K. pneumoniae 10D60 16 R 2 S 8
K. pneumoniae 10F53 16 R 2 S 8
K. pneumoniae 10F74 32 R 8 R 4
K. pneumoniae 1-57 16 R 2 S 8
K. pneumoniae 1-60 16 R 4 I 4
K. pneumoniae 1-61 128 R 128 R 0
K. pneumoniae 1-70 32 R 4 I 8
K. pneumoniae 10I28 16 R 0.5 S 32
E. coli08Y79 8 R 2 S 4
E. coli 09B20 2 S 0.5 S 4
E. coli 09D25 2 S ≤ 0.25 S ≥ 8
E. coli 1-37 1 S ≤ 0.25 S ≥ 4
E. coli 1-47 16 R 4 I 4
E. coli 10F75 2 S 2 S 0
E. coli 2-4 2 S 0.5 S 4
aEUCAST breakpoints [61]: resistant MIC ≥ 8 mgL1; susceptible MIC ≤ 2 mgL1. (CLSI breakpoints are resistant MIC ≥ 4 mgL1; suscep-
tible MIC ≤ 1 mgL1 [58]).
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to make an electrostatic interaction with Zn2 (distance
2.37 A), with the consequence that Zn2 is fivefold
coordinated in a trigonal bipyramidal geometry.
Water-mediated interactions reminiscent of those
observed in carbapenem complexes (see below) connect
one oxygen atom of the inhibitor C1 carboxylate to
the Ala231 carbonyl and His224 Nd1, and, via an
additional water molecule, to the Asn233 backbone
amide. An additional water molecule, Wat3, connects
the Zn2-bound oxygen to the Cys221 carbonyl. The
trichlorine substituted phenyl ring of ML302F makes
a p-stacking interaction with Phe61 at the base of loop
L3, with one of the halogen atoms making a chlorine-
p interaction with Trp87.
Interactions of VIM-1 with hydrolysed
meropenem
Although recent progress has been made in structural
characterization of the interactions of B1 MBLs with
hydrolysed b-lactam substrates [33–36], to date there is
no reported information on how VIM enzymes bind
their b-lactam substrates. Given the clinical impor-
tance of the VIM enzymes, and their lack of Lys224, a
residue likely crucial in the interaction of most other
B1 MBLs with the C2/C3 carboxylate group of b-lac-
tams, information regarding the mode of b-lactam
binding to VIM-1 is important both to understanding
the mechanism of b-lactam hydrolysis and design of
inhibitors. Hence, to investigate the interactions of
VIM-1 with b-lactams, we soaked native VIM-1 crys-
tals with meropenem with the aim of obtaining struc-
tural information on enzyme-bound species.
Inspection of Fo  Fc difference density maps calcu-
lated from a diffraction data set collected from a
native VIM-1 crystal after overnight exposure to
meropenem powder revealed positive density peaks
into which hydrolysed meropenem could be refined
(Fig. 4A). This yielded a structure for a complex to a
resolution of 2.20 A. The structure contains 232 amino
acids with five residues missing from the N terminus
and three from the C terminus. Four residues were
built with alternative side chain conformations. Zinc
ions were refined in the Zn1 (occupancy 1.0) and Zn2
(occupancy 0.87) sites, with a third zinc ion (occu-
pancy 0.55) involved in crystal contacts at the interface
of VIM-1 molecules in two adjacent asymmetric units.
Notably, Zn2 presented a higher than average B-factor
(33.67 A2 compared to 13.18 A2 for Zn1).
Compared to the VIM-1:ML302F complex, binding
of hydrolysed meropenem to VIM-2 is less well defined
– in addition to the lower resolution, elevated
B-factors were observed for the hydrolysed meropenem
ligand (overall B-factor of 39.13 A2 compared to
16.99 A2 for the protein main chain). Nevertheless,
refining the ligand at full occupancy yielded a
Fig. 3. Interactions of thioenolate inhibitor ML302F with VIM-1. (A) Structure of ML302F:VIM-1 Complex. VIM-1 main chain Ca atoms are
colour ramped from blue (N terminus) to red (C terminus). Active site residues are rendered as sticks; zinc ions as grey spheres, water
molecules as red spheres. Inhibitor carbon atoms are in cyan, side chain carbons in green. Other atom colours are as standard. Electron
density shown is |Fo|  |Fc| Φcalc contoured at 3 r around inhibitor and calculated with the ligand omitted. Hydrogen bonding interactions are
shown as dashed lines. Inset shows structure of ML302F. (B) Map of VIM-1–ML302F interactions. Zinc ions are rendered in green; water
molecules in cyan; other atom colours as standard. The figure was generated using LIGPLOT [59].
175The FEBS Journal 286 (2019) 169–184 ª 2018 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
R. Salimraj et al. Substrate/inhibitor binding by VIM-1 b-lactamase
real-space correlation coefficient of 0.85 and real-space
R-value of 0.25; parameters that indicate acceptable
agreement of observed and calculated electron densi-
ties for bound ligand [37]. This is confirmed by visual
inspection; omit (|Fo|  |Fc| Φcalc; Fig. 4A) electron
density maps define the positions of key elements of
hydrolysed meropenem – the dihydropyrrole ring and
associated N4 nitrogen and C3 carboxylate groups,
and the S atom and pyrrolidine ring of the C2 sub-
stituent. Appropriate ligand placement is also evident
based on inspection of 2|Fo|  |Fc| Φcalc and associated
difference (|Fo|  |Fc| Φcalc) maps (Fig. 4B), with the
latter providing no strong negative peaks indicating
substantial errors in ligand placement. However, omit
electron density is weaker for the methyl group
attached to C1, the carbapenem C6 hydroxyethyl
group and, in particular for the C7 carboxylate that is
formed on hydrolysis of the b-lactam ring. This was
positioned after trial refinements in several alternative
orientations, including in the zinc-bridging position,
with the final structure representing the mode of bind-
ing that minimised overly close contacts with Zn ions
and coordinating residues, such as Asp120, and steric
clashes of the C6 hydroxyethyl with the adjacent side
chains of Phe61 and Trp87. Hence, as in the uncom-
plexed VIM-1 structure, Wat1 is closer to Zn1
(1.84 A) than Zn2 (2.28 A, Fig. 5A,B), and the pres-
ence of hydrolysed meropenem has little effect on the
Zn–Zn separation distance (3.52 A compared to
3.62 A in the uncomplexed structure).
Carbapenems contain a 4 : 5 fused b-lactam ring
system with a double bond between C2 and C3 in the
five-membered pyrroline ring. This results in two pos-
sible tautomeric forms (D1 and D2 pyrroline) for the
product resulting from hydrolysis of the b-lactam ring
(Fig. 5C [10,38]). In intact meropenem the C2/C3 car-
bon atoms are sp2 hybridised, due to the double bond
between them, and are coplanar with the C2-linked S
Fig. 4. Electron density maps for hydrolysed meropenem bound to VIM-1. (A) Stereoview of |Fo|  |Fc| Φcalc electron density (green;
calculated with ligand omitted) contoured at 2.5 r around hydrolysed meropenem (cyan). Note the position of the S atom out of the plane
of the pyrroline ring. (B) Stereoview of 2|Fo|  |Fc| Φcalc electron density (blue) and |Fo|  |Fc| Φcalc electron density (negative peak red; both
calculated with ligand included) contoured at 1.0 and 3.0 r respectively, around hydrolysed meropenem (cyan). Note the presence of only
very limited negative density close to the C7 carboxylate. Active site residues are rendered as sticks; zinc ions as grey spheres, water
molecules as red spheres. Other atom colours are as standard.
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atom. This configuration can be retained after b-lac-
tam hydrolysis. However, in ring-opened carbapenems
tautomerization of the enamine double bond can
occur, giving rise to the D1 (imine) form with a double
bond between C3 and N4. Our experimental data, at
2.2 A resolution, cannot permit unambiguous assign-
ment of the tautomeric form present. However, experi-
mental difference electron density maps (Fig. 4A)
indicate the S atom as lying out of the plane of the
pyrroline ring, suggesting that the meropenem C2 is
sp3, rather than sp2, hybridized. In consequence, we
have refined the ligand in the D1 (imine), rather than
the D2, tautomer, and in the (S) (b), rather than (R)
(a) stereochemistry (Figs 4 and 5).
These limitations notwithstanding, the compara-
tively strong electron density observed for elements of
the ligand interacting with the MBL metal centre (N4
nitrogen and C3 carboxylate groups) defines key inter-
actions of VIM-1 with hydrolysed meropenem
(Fig. 5A,B) that involve the Zn2 metal ion. Zn2 dis-
plays octahedral co-ordination, contacting O1 of the
substrate C3 carboxylate (in the Wat2 position of the
native active site, 2.57 A) and N4 of the hydrolysed
b-lactam-derived amine. However, the Zn2–N4 interac-
tion is apparently weak (3.02 A) compared to the
equivalent contacts in other complexes of MBLs with
hydrolysed b-lactams (possibly reflecting more facile
release of hydrolysis product by VIM-1). The C3 car-
boxylate is also positioned to make additional
interactions with the enzyme, both directly (via its O2
atom and the backbone amide of Asn233; 2.68 A) and
indirectly (between O2 and the imidazole side chain of
His224 via an additional water, and between O1 and
the main chain carbonyl of Cys221 via a water mole-
cule in the Wat3 position). Wat3 thus plays similar
roles in carboxylate binding in both the meropenem
and ML302F complex structures.
Discussion
Clinically relevant MBLs are largely contained within
the B1 subclass. The VIM enzymes are among the
most important and are noted for their wide bacterial
species and geographical distribution and diversity (60
variants at the time of writing). Variation in VIM
enzymes is notable as it occurs at two positions, 224
and 228, that are proposed to interact with b-lactam
substrates in other MBLs [23], raising the possibility
that different variants bind ligands (substrates or inhi-
bitors) in different ways. Different variants feature
Tyr, His or Leu at position 224 and Arg, Ser or Leu
at 228. Thus, while VIM-2 Arg228 is proposed to con-
tact the substrate carboxylate as a functional equiva-
lent of Lys224 in other B1 MBLs [24,39], other VIM
variants can be expected to interact with this key
b-lactam functional group in different ways.
Binding of the thioenolate inhibitor ML302F to
VIM-1 gives insight into how different VIM variants
Fig. 5. Interactions of hydrolysed meropenem with VIM-1. (A) Interactions made by hydrolysed meropenem with VIM-1 active site.
Hydrogen bonds are shown as dashed lines. (B) Map of VIM-1 interactions with hydrolysed meropenem. Zinc ions are rendered in green;
water molecules in cyan; other atom colours as standard. (C) Structure of intact and hydrolysed meropenem in D2 (B) and D1 (C) pyrroline
forms.
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might interact with both inhibitors and substrates. Pre-
vious studies [30,40] identified ML302F as a low
micromolar inhibitor of both VIM-1 and VIM-2 that
potentiates meropenem activity against VIM-expres-
sing laboratory and clinical Enterobacteriaceae in sus-
ceptibility testing and promotes survival of infected
insect (Galleria) larvae [40]. The current work extends
these observations by demonstrating activity of the
ML302F–meropenem combination against a wider
panel of VIM-1 producing clinical strains. Moreover,
when considered with the existing VIM-2:ML302F
structure [30], our structure of the VIM-1:ML302F
complex enables, for the first time, direct comparison
of how the same ligand is bound by two different
VIM variants (Fig. 6A).
ML302F is almost identically positioned in the
two structures. Similar to VIM-1 binding (above), the
ML302F thiol intercalates between the two zinc ions
and the carboxylate interacts with the VIM-2 Zn2 ion.
In addition, the ML302F carboxylate makes direct
(hydrogen bond) contact with the guanidinium side
chain of VIM-2 Arg228. In VIM-1, the equivalent oxy-
gen of the ML302F carboxylate makes a water-
mediated interaction with His224. However, in both
complexes the ML302F Zn2-bound oxygen atom also
interacts with the backbone carbonyl of the Zn2 ligand
Cys221 via a water molecule, Wat3. Wat3 adopts
near-identical positions in the VIM-1 and VIM-2 com-
plexes, implying a conserved role in substrate/inhibitor
carboxylate binding. This conclusion is further sup-
ported by near-identical interactions in complexes of
VIM-2 with cyclic boronate [41] and triazolylthioac-
etamide [42] inhibitors, that similarly involve Wat3 in
binding carboxylate.
Involvement of Wat3 in ML302F binding by VIM-1
and VIM-2, along with the similarity between
ML302F binding to VIM-2 and interactions of hydrol-
ysed b-lactams with other B1 MBLs [30], suggests that
VIM enzymes might make equivalent contacts with b-
lactams. Indeed, comparison of our ML302F and mer-
openem VIM-1 complexes indicates that the oxygen
atoms of the ML302F C1 and meropenem C3 car-
boxylates adopt near-identical positions and, impor-
tantly, make equivalent interactions with the VIM-1
active site (Fig. 6B). In both cases the Zn2-bound oxy-
gen contacts the Cys221 backbone carbonyl via Wat3,
supporting involvement of Wat3 in b-lactam, as well
as inhibitor, binding by VIM-1 and, by implication,
other VIM enzymes. The other carboxylate oxygen
hydrogen bonds, via a water molecule, to His224, thus
providing a mechanism for involvement of this residue
in substrate binding, although it is too distant
(> 5.7 A) from the meropenem carboxylate to make a
direct interaction. Increases in KM values (i.e. reduced
affinity) for carbapenem and some cephalosporin sub-
strates for VIM-26 (VIM-1 His224Leu) compared to
VIM-1 [25] also support the involvement of VIM-1
His224 in b-lactam binding. However, the fact that
VIM-26 retains catalytic activity shows that a residue
at position 224 able to make electrostatic interactions
with substrate is not essential to activity of VIM
enzymes.
Until now, structures of complexes of VIM MBLs
with hydrolysed b-lactams have been elusive. However,
these are available for the B1 MBL NDM-1, permit-
ting comparison of meropenem binding to VIM-1 with
b-lactam binding to NDM-1. In such structures, the
C2/C3 carboxylates of hydrolysed penicillins [34–36],
cephalosporins [33] and carbapenems [35,43] contact
the NDM-1 Zn2 metal ion, the backbone amide of
Asn233 and the terminal amino group of Lys224.
Comparing hydrolysed meropenem binding to VIM-1
and NDM-1 (Fig. 6C), in each case the C2 carboxylate
adopts similar orientations and makes equivalent inter-
actions with Zn2 and the Asn233 backbone amide; but
the two complexes differ in the interactions made by
the Zn2-bound carboxylate oxygen, which in NDM-1
hydrogen bonds to Lys224 and in VIM-1 to the
Cys221 backbone carbonyl via Wat3. Wat3
thus enables VIM-1, and by implication other VIM
enzymes, to replicate interactions with substrates made
by Lys224 in other B1 MBLs. The importance of these
to b-lactam binding and hydrolysis is evidenced by the
profound loss of activity observed in Lys224 mutants
of other B1 enzymes [44–46]. Thus, in both of the
structures presented here, as well as the ML302F:
VIM-2 complex, the water molecule Wat3 connects the
carboxylate of hydrolysed b-lactam/inhibitor to the
Cys221 backbone carbonyl. These observations indi-
cate that Wat3 enables VIM enzymes to replicate the
role of Lys224 in ligand binding by other subclass B1
MBLs, while simultaneously accommodating sequence
variations at positions 224 and 228. To investigate this
hypothesis, we inspected crystal structures of VIM
MBLs (Fig. 6D). This analysis identified water mole-
cules in the Wat3 position in all available VIM variant
structures and their complexes in the active (binuclear)
form. We thus propose that this active site water mole-
cule, positioned by the backbone of the invariant Zn2
ligand Cys221, enables different VIM variants to make
productive interactions with substrate even where, as
in VIM-1, direct contact between the C2/C3 carboxy-
late and protein is impossible.
Mechanistic interpretation of the complex with
bound meropenem is limited by both the resolution of
our data, and the weak electron density for the C6
178 The FEBS Journal 286 (2019) 169–184 ª 2018 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
Substrate/inhibitor binding by VIM-1 b-lactamase R. Salimraj et al.
hydroxyethyl and C7 carboxylate groups. The situa-
tion is further complicated by the likelihood that sev-
eral species are likely to be present, given that
carbapenem breakdown in solution can yield a mixture
of hydrolysis products, that is, both the D1 (R and S
stereoisomers) and D2 tautomers [47] and that trapped
complexes may thus represent either species present on
the late stages of the reaction pathway or rebinding of
Fig. 6. Importance of Cys221-bound water to ligand binding by VIM-1. (A) Mode of ML302F binding to VIM-1 (green) and VIM-2 (pdb 4PVO
[30]; blue). Wat3 in VIM-2 structure is in dark red. (B) Overlay of ML302F and hydrolysed meropenem complexes with VIM-1. The active
site view of the ML302F complex is shown in lighter, and meropenem in darker, shades. (C) Overlay of hydrolysed meropenem binding to
VIM-1 (darker colours) and NDM-1 (pdb 5N0H [35,60]; lighter colours). (D) Overlay of available VIM crystal structures (details as Fig. 1)
showing conserved location of Wat3. Colours are as specified. Note how Wat3 mediates interactions of both substrate and inhibitor
carboxylate groups with the Cys221 backbone carbonyl, and substitutes for NDM-1 Lys224 in binding the carboxylate of hydrolysed
meropenem (Panel C).
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highest affinity products present in solution. However,
we note that in the present structure the well-defined
meropenem N4 atom lies more distant (3.02 A) from
Zn2 than in other such complexes with B1 MBLs,
where this is typically a tight interaction (≤ 2.40 A).
When considered together with our inclusion of a zinc-
bridging water molecule in our final model, (which is
consistent with available structures for NDM-1–peni-
cillin and cephalosporin-derived complexes [33–36]),
one possible interpretation is that our complex could
represent a stage in product release where water has
displaced the C7 carboxylate from the Zn-bridging
position. This would indicate that release of product
from the MBL active site is not a single step process,
and that interactions of b-lactams around the Zn2 site
persist longer than those involving Zn1.
Overall, our work provides the first structural
description of VIM-1, an MBL of particular relevance
to the growing problem of carbapenem-resistant Enter-
obacteriaceae. Our structures of VIM-1–meropenem
and inhibitor complexes establish how VIM MBLs
accommodate variation at residues 224 and 228, with-
out loss of activity, and provide new information on
carbapenem hydrolysis, specifically related to product
release. Identification of interactions, involving car-
boxylate groups of small molecule ligands and the
invariant water molecule Wat3, that are common to
VIM-1, VIM-2 and, we infer, other VIM variants, will
aid in structure-based rational development of effective
inhibitors for the full range of these heterogeneous and
clinically important enzymes.
Experimental procedures
Materials
General laboratory reagents were purchased from Sigma
(Poole, UK) or VWR (Lutterworth, UK) and were of ana-
lytical grade. Inhibitor ML302F was synthesized as previ-
ously described [30]. Meropenem was a gift from
AstraZeneca (Macclesfield, UK).
Cloning, expression and purification
Full-length VIM-1 with a C-terminal 6His tag was
expressed and purified largely according to previously pub-
lished procedures [48] using the pOPINE T7 plasmid [49]
containing a synthetic codon optimized gene. Modifications
are detailed below. Protein was expressed in E. coli Rosetta
2 (DE3) (Merck, Watford, UK) with cells (500 mL in 2 L
conical flasks) grown in Terrific Broth autoinduction media
(Formedium, Hunstanton, Norfolk, UK) supplemented
with 100 lgmL1 ampicillin. Cultures were grown at 37 °C
shaking at 160 r.p.m. for 8 h; the temperature was
subsequently lowered to 25 °C for overnight growth. Cul-
tures were harvested by centrifugation (7 200 g, 30 min,
4 °C) and pellets from 3 L cells resuspended in 200 mL of
buffer A (50 mM Tris pH 7.5, 500 mM NaCl, 30 mM imida-
zole) supplemented with 20 lL of 5 kU benzonase (Sigma
Aldrich, Poole, UK), 0.02% Tween 20 (Sigma) and two
EDTA-free protease inhibitor cocktail tablets (Roche, Bur-
gess Hill, UK). A Constant Cell Disruption System
(Constant Systems, Daventry, UK) was used to lyse
homogenized cells at 25 kpsi, the lysate was cleared by cen-
trifugation (1 h, 38 500 g, 4 °C). 6His-tagged VIM-1 was
purified on a 5-mL HisTrap HP column (GE Life Sciences,
Little Chalfont, UK) using a 0–500 mM imidazole gradient,
as described [48]. Protein obtained from this single-step
purification was estimated as being over 98% pure as
adjudged by SDS/PAGE. Fractions containing VIM-1 were
pooled and concentrated by centrifugation (10 kDa molec-
ular weight cut off Amicon Ultra-15 (Merck). Protein used
to obtain the di-zinc VIM-1 structure was further purified
by size exclusion (Superdex-200) as described [48]; samples
used to obtain other structures were used without further
purification.
Crystallization, data collection and structure
solution
Crystallization screening used commercial sparse matrix
screens (Molecular Dimensions, Newmarket, UK; Qiagen,
Manchester, UK) dispensed via a Hydra 96 microdispenser
(Robbins Scientific, Sunnyvale, CA, USA). A Honeybee X8
(Digilab, Hopkinton, MA, USA) robot was used to set up
crystallization trials in 96-well sitting drop plates (Crys-
talQuick, Greiner, Stonehouse, UK) with drops containing
0.1 lL of protein and 0.1 lL of reservoir solution and a
total reservoir volume of 95 lL. Crystals were stored and
monitored at 21C using a Rock Imager 1000 system (For-
mulatrix, Bedford, MA, USA). The di-zinc VIM-1 structure
was solved using a crystal obtained from protein concen-
trated to 15 mgmL1 (containing 7% glycerol) and crystal-
lized under conditions (0.05 M MgCl2, 0.03 M CaCl2, 0.1 M
Morpheus buffer 3 pH 8.5, 13.5% w/v poly(ethylene glycol)
3350, 9.5% w/v poly(ethylene glycol) 1000 and 12.5% w/v
MPD) obtained by optimization of an initial hit from the
Morpheus screen [50]. This crystal was obtained from a
drop set up by hand in 24-well hanging drop format using
1 lL protein and 1 lL reservoir condition and a total
reservoir volume of 500 lL.
Other VIM-1 structures were obtained from protein con-
centrated to ~ 23 mgmL1 containing 10% glycerol and
supplemented with 100 lM ZnCl2, 2 mM tris(2-carbox-
yethyl)phosphine (Thermo Scientific, Loughborough, UK).
Crystals of the VIM-1:ML302F complex were obtained
from 0.02 M Na-formate, 0.02 M NH4-acetate, 0.02 M Na3-
citrate, 0.02 M NaK-tartrate, 0.02 M Na-oxamate, 0.1 M
Morpheus Buffer 1 pH 6.5, 12.5% w/v poly(ethylene
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glycol) 3350, 12.5% w/v poly(ethylene glycol) 1000 and
12.5% w/v MPD. Crystallization drops were set up by
hand in 96-well MRC sitting drop plates (Molecular
Dimensions) using commercial screens with 0.5 lL of pro-
tein and 0.5 lL reservoir solution and a total reservoir vol-
ume of 50 lL. Experiments were incubated at 20 °C.
Excess inhibitor was added to the drop in the form of pow-
der. The structure of the VIM-1–meropenem complex was
obtained from an overnight soak of crystals obtained from
a different Morpheus condition (0.1 M MOPS/HEPES-Na
pH 7.5, 12.5% w/v poly(ethylene glycol) 1000, 12.5% w/v
poly(ethylene glycol) 3350, 0.03 M CaCl2, 0.03 M MgCl2
and 12.5% v/v MPD) with excess substrate powder. Crys-
tals were snap-frozen in liquid nitrogen prior to transporta-
tion for diffraction data collection.
Crystallographic data were collected at 100 K on beamli-
nes of Diamond Light Source (DLS; Didcot, UK) using Pila-
tus 6M-F detectors. Diffraction data were integrated with
XDS and scaled using AIMLESS as part of the CCP4 software
suite [51–53]. Phases were solved by molecular replacement
in PHASER [54] using either VIM-4 (PDB 2WGH [29]) or pre-
viously determined VIM-1 structures as search models.
Rounds of refinement were carried out using PHENIX [55] with
manual rebuilding in COOT [56]. MOLPROBITY [57] was used for
structure validation as part of the PHENIX suite. PYMOL (www.
pymol.org) was used to generate figures. Data collection and
refinement statistics, together with Protein Data Bank (pdb)
accession codes, are presented in Table 1.
Determination of minimal inhibitory
concentrations
Twenty clinical strains of K. pneumoniae and seven clinical
strains of E. coli, originating from clinical specimens from
Spain, were confirmed for the presence of VIM-1 by PCR
assay using the primers VIM-F (50-CCG ACA GTC ARC
GAA ATT CCG-30) VIM-R (50-CTA CTC RRC GAC
TGA GCG ATT-30). MIC values were determined by broth
microdilution, in triplicate, in cation-adjusted Mueller–Hin-
ton broth (Sigma) according to the Clinical Laboratory
Standards Institute (CLSI) guidelines [58]. Experiments
were carried out in microtitre plates (Corning) containing
the medium plus meropenem and inhibitor ML302F [dis-
solved in DMSO and added to the wells with a final con-
centration of 10 lgmL1 (0.1% DMSO)]. Plates were
incubated overnight at 37 °C for 18–24 h and absorbance
at 600 nm read using a Polarstar Omega (BMG LabTech,
Aylesbury, UK) plate reader.
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